Intrexon Reports Sharp Rise in Q3 Revenues | GenomeWeb

NEW YORK (GenomeWeb News) – Reporting for the first time as a public company, synthetic biology company Intrexon said after the close of the market on Thursday that revenues in its third quarter more than doubled year over year.

Total revenues for the three months ended Sept. 30 reached $6.1 million, up from $2.9 million a year ago, driven by an uptick in collaboration revenues, which increased to $6.0 million from $2.9 million a year ago. Other revenues were up to $105,000 from $21,000.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The White House has created a list of cuts, including to the NIH, that could be in a budget bill for this year.

The US National Institutes of Health is to allow applicants to cite preprints just as they would any other research paper, ScienceInsider reports.

Two manuscript pages handwritten by Charles Darwin are going on the auction block, according to the Los Angeles Times.

In PNAS this week: tool to track transcriptome-wide binding, evidence of balancing selection on behavior-linked genes, and more.